吸入α1-抗胰蛋白酶治疗严重α1-抗胰蛋白酶缺乏症合并频繁COPD急性加重患者的疗效与安全性
本研究将168例遗传性α1-抗胰蛋白酶缺乏症(ZZ-AATD)合并严重COPD且频繁急性加重的患者随机分配至每日两次吸入80 mg AAT溶液或安慰剂组,治疗50周。主要终点首次事件性急性加重时间在两组间无显著差异(p=0.0952),AAT组治疗相关不良事件发生率高于安慰剂组(57.5% vs 46.9%),但研究第一年后调整雾化器处理后AAT组安全事件发生率降至安慰剂组水平。结论认为吸入AAT对首次急性加重时间无影响,但可能改变了急性发作的模式。
要点
- 吸入AAT未显著延长COPD频繁急性加重患者的首次急性加重时间(p=0.0952)。
- AAT组治疗相关不良事件发生率高于安慰剂组(57.5% vs 46.9%),退出研究比例更高。
- 调整雾化器处理后,AAT组安全事件发生率降至与安慰剂组相当。
核心结论
- 在严重COPD且频繁急性加重的AATD患者中,吸入AAT 50周对首次急性加重时间无显著影响,但可能改变了急性发作的模式。
研究设计与样本
- 随机对照试验,168例遗传性α1-抗胰蛋白酶缺乏症(ZZ-AATD)合并严重COPD且频繁急性加重的患者随机接受每日两次吸入80 mg AAT溶液或安慰剂,治疗50周。
主要发现
- 首次中度或重度急性加重时间中位数:AAT组112天(IQR 40-211天),安慰剂组140天(IQR 72-142天),p=0.0952。
- 所有急性加重年均发生率:AAT组3.12次,安慰剂组2.67次,p=0.31。
- 治疗相关治疗中出现的不良事件发生率:AAT组57.5%,安慰剂组46.9%,AAT组退出研究比例更高。
- 研究第一年后调整雾化器处理后,AAT组安全事件发生率降至安慰剂组水平。
临床怎么用
- 对于严重COPD且频繁急性加重的ZZ-AATD患者,吸入AAT未能显著延长首次急性加重时间,不推荐仅以此为目的使用。
- 使用吸入AAT时应关注治疗相关不良事件及患者耐受性,必要时调整雾化器处理方式可能改善安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with inherited α1-antitrypsin (AAT) deficiency (ZZ-AATD) and severe chronic obstructive pulmonary disease (COPD) frequently experience exacerbations. We postulated that inhalation of nebulised AAT would be an effective treatment.We randomly assigned 168 patients to receive twice-daily inhalations of 80 mg AAT solution or placebo for 50 weeks. Patients used an electronic diary to capture exacerbations. The primary endpoint was time from randomisation to the first event-based exacerbation. Secondary endpoints included change in the nature of the exacerbation as defined by the Anthonisen criteria. Safety was also assessed.Time to first moderate or severe exacerbation was a median of 112 days (interquartile range (IQR) 40-211 days) for AAT and 140 days (IQR 72-142 days) for placebo (p=0.0952). The mean yearly rate of all exacerbations was 3.12 in the AAT-treated group and 2.67 in the placebo group (p=0.31). More patients receiving AAT reported treatment-related treatment-emergent adverse events compared to placebo (57.5% versus 46.9%, respectively) and they were more likely to withdraw from the study. After the first year of the study, when modifications to the handling of the nebuliser were introduced, the rate of safety events in the AAT-treated group dropped to that of the placebo group.We conclude that in AATD patients with severe COPD and frequent exacerbations, AAT inhalation for 50 weeks showed no effect on time to first exacerbation but may have changed the pattern of the episodes.
引用
- Stolk J, Tov N, Chapman KR, et al. Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD. Eur Respir J. 2019. PMID: 31467115. doi:10.1183/13993003.00673-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。